The IMPACT Initiative
As the leading cause of death and a major cause of disability in Western countries, cardiovascular disease (CVD) continues to grow in developing countries. Proper lipid control is one of the most effective strategies for CVD prevention; a concept that has been demonstrated again and again in clinical trials. These trials have consistently established that aggressive reduction of LDL-C levels in the blood reduces CV risk in the settings of secondary prevention and high-risk primary prevention.
Familial hypercholesterolemia (FH) is a genetic disorder in which gene mutations prevent removal of excess cholesterol from the blood stream. The heterozygous form (inherited from one parent) affects about 1 in 250 people in the US; while the homozygous form (inherited from both parents) is much more severe and rare, affecting about 1 in every 300,000 people.1
Familial Hypercholesterolemia
- Heterozygous (1 inherited gene): ~1/250 people
- Homozygous (2 inherited genes): ~1/300,000 people
Our IMPACT program is an online tool that aims to provide clinicians and patients with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for individuals with FH who are at high risk for CVD. Our goal is to provide information that empowers clinicians and patients to speak openly about treatment decisions and improve the standard of care for patients with this difficult-to-treat type of dyslipidemia.
Reference
- Family Heart Foundation. Homozygous FH. https://familyheart.org/familial-hypercholesterolemia/homozygous-familial-hypercholesterolemia
Clinician Scientific &
Educational Resources
Patient & Caregiver
Educational Resources
Familial hypercholesterolemia (FH) is a genetic disorder in which gene mutations prevent removal of excess cholesterol from the blood. Heterozygous FH (inherited from one parent) affects in excess of 1 million people in the US; while the homozygous form (inherited from both parents) is much more severe and rare, affecting around 1,300 US individuals.
Our IMPACT program is an online tool that aims to provide clinicians and patients with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for individuals with FH who are at high risk for CVD.
